错配修复缺陷结直肠癌:基于检查点阻断的进展
错配修复缺陷(dMMR)结直肠癌(CRC)因超突变产生丰富新抗原并激活抗肿瘤免疫。免疫检查点抑制剂(ICI)可带来频繁且持久的缓解并延长生存;帕博利珠单抗单药已成为dMMR转移性CRC(mCRC)新标准治疗,PD-1与CTLA-4联合较单药PD-1更有效,但部分肿瘤存在原发或获得性耐药,需生物标志物识别。
要点
- dMMR mCRC一线帕博利珠单抗较化疗显著延长无进展生存且不良事件更少。
- 单药帕博利珠单抗为dMMR mCRC新标准治疗,涵盖Lynch综合征与散发病例。
- PD-1联合CTLA-4抑制在dMMR mCRC中较单药PD-1更有效,提示非冗余机制。
核心结论
- 单药帕博利珠单抗已成为dMMR mCRC(包括Lynch综合征及更常见的散发病例)的新标准治疗。
- PD-1与CTLA-4抑制剂联合在dMMR mCRC中较单药PD-1抑制更有效,提示非冗余作用机制。
- 相当比例dMMR肿瘤存在原发或获得性ICI耐药,需要生物标志物识别这些患者。
研究设计与样本
- 综述,全面概述免疫治疗在dMMR CRC中作用的证据、耐药机制及克服原发与继发耐药的潜在策略。
主要发现
- dMMR CRC以超突变为特征,导致丰富新抗原并激活肿瘤微环境中的抗肿瘤免疫反应。
- ICI通过产生频繁且持久的缓解并延长患者生存,改变了dMMR CRC及其他dMMR实体瘤的治疗。
- 帕博利珠单抗一线治疗dMMR mCRC较化疗显著延长无进展生存且不良事件更少。
- PD-1与CTLA-4抑制剂联合在dMMR mCRC中较单药PD-1抑制更有效。
- ICI获益目前限于转移性疾病,评估ICI用于早期dMMR CRC新辅助和辅助治疗的研究正在进行。
临床怎么用
- 单药帕博利珠单抗作为dMMR mCRC(包括Lynch综合征及散发病例)的新标准治疗。
局限性
- ICI的获益目前限于转移性疾病。
- 相当比例dMMR肿瘤存在原发或获得性耐药,需要生物标志物识别这些患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by hypermutation leading to abundant neoantigens that activate an antitumor immune response in the tumor microenvironment. Immune checkpoint inhibitors (ICIs) have transformed the treatment of this subset of CRC and other solid tumors with dMMR, by producing frequent and durable responses that extend patient survival. Recently, the anti-programmed death-1 (PD-1) antibody pembrolizumab was shown to produce significantly longer progression-free survival with fewer adverse events compared with chemotherapy as first-line treatment of metastatic CRC (mCRC) with dMMR. Accordingly, single-agent pembrolizumab represents a new standard of care for dMMR mCRCs including patients with Lynch syndrome and the more common sporadic cases. Furthermore, data indicate that the combination of PD-1 and cytotoxic T-cell lymphocyte-4 inhibitors was more effective than single-agent PD-1 inhibition in patients with dMMR mCRCs, suggesting nonredundant mechanisms of action. Although the benefit of ICIs is currently limited to metastatic disease, studies evaluating ICIs as neoadjuvant and adjuvant therapy in earlier-stage dMMR CRC are ongoing. Despite success of ICIs in the treatment of metastatic dMMR cancers, an appreciable proportion of these tumors demonstrate intrinsic or acquired resistance, and biomarkers to identify these patients are needed. Advances in the understanding of immunotherapy resistance mechanisms hold promise for both biomarker identification and development of novel strategies to circumvent treatment resistance. In this review, we present a comprehensive overview of the evidence for the role of immunotherapy in the treatment of dMMR CRC, discuss resistance mechanisms, and outline potential strategies to circumvent primary and secondary resistance with the goal of broadening the benefit of ICIs.
引用
- Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022. PMID: 35649217. doi:10.1200/JCO.21.02691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。